Table 1.
Survey trials on pancreatic cancer treatments including hyperthermia
| Trials on advanced pancreatic cancer | Center | Hyperthermia method | No of patients | Control arm (%) | Arm adding hperth. (%) | Overall Survival (OS) benefit in arm including hyperthermia | Benefit OS odds ratio | Benefit quality of life |
|---|---|---|---|---|---|---|---|---|
| Kouloulias et al. 2002 [6] | Athens, Greece | Intrasurgery surface heating | 65 | 85 % | 15 % | 11 months (SE 2.4 months) | p = 0.029 | Better: p = 0.031 |
| Yamada et al. 1992 [5] | Sendai, Japan | Intrasurgery surface heating | 69 | 80 % | 20 % | 1 year OS:plus 6.9 % | Only marginally better | |
| 2. year plus 4.2 % | ||||||||
| Mi et al. 2013 [10] | Meta-analysis for adv. gastric cancers | Intraoperative HIPEC-thermoenhanced Chemotherapy | 1906 in 16 rand. trials | 1. year OS | 2.99 (95 % Cl) 2.21 to 4.05; p < 0.00001 | No higher risks; but increase incidences of abdominal pain | ||
| Hager et al. 2006 [24] | Bad Bergzabern, Germany | Non-invasive loco-reg. heating | 46 | 100 % | Median OS: 10.8 months | QoL improvement & pain decrease (56 %) | ||
| 1. year OS: 41 % | ||||||||
| Zhang et al. (2008) [30] | China | Non-invasive loco-reg. heating | 75 | 49 % | 51 % | 1. year OS plus 13 % | No serious complicat. | |
| 2. year OS plus 50 % | ||||||||
| Mueller-Huebenthal 2010 [25] | Stuttgart, Germany | Non-invasive loco-reg. heating | 25 | 100 % | Median OS 12.2 months | Pain reduction observed | ||
| 1. year OS: 51 % | ||||||||
| Maluta et al. 2011 [31] | Verona, Italy | Non-invasive loco-reg. heating | 60 | 50 % | 50 % | OS plus 4 months = +36 % | p = 0.025 | No increased toxicity |
| Ishikawa et al. 2012 [32] | Multicentre Japan | Non-invasive loco-reg. heating | 18 | 100 % | Median OS: 8 months; 1 year OS: 33 % | No added toxicity except mild pain & skin rush | ||
| Tschoep-Lechner 2013 [33] | Munich, Germany | Non-invasive loco-reg. heating | 23 | 100 % | Median OS 12.9 months |